Global InformationXywav information
| Combination of | |
|---|---|
| Calcium oxybate | Central nervous system depressant |
| Magnesium oxybate | Central nervous system depressant |
| Potassium oxybate | Central nervous system depressant |
| Sodium oxybate | Central nervous system depressant |
| Clinical data | |
| Trade names | Xywav |
| Other names | JZP-258 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a621001 |
| License data |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG |
|
Xywav is a medication used to treat cataplexy or excessive daytime sleepiness.[2][3] It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate.[2] It is a central nervous system (CNS) depressant and it is taken by mouth.[2]
Manufactured by the Jazz Pharmaceuticals company, it was approved for medical use in the United States in July 2020.[2][4][5]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ a b c d e "Xywav - calcium, magnesium, potassium, and sodium oxybates solution". DailyMed. Archived from the original on 13 August 2021. Retrieved 12 August 2021.
- ^ Halter MJ, Fratena CA (November 2021). "Sleep-Wake Medications". Varcarolis' Manual of Psychiatric Nursing Care. Elsevier Health Sciences. p. 398. ISBN 978-0-323-79306-3. Archived from the original on 20 June 2022. Retrieved 23 December 2021.
- ^ "Drug Approval Package: Xywav". U.S. Food and Drug Administration (FDA). 7 May 2021. Archived from the original on 13 August 2021. Retrieved 12 August 2021.
- ^ "Drug Approval Package: Xywav". U.S. Food and Drug Administration (FDA). 7 May 2021. Archived from the original on 27 December 2021. Retrieved 19 November 2021.